Skip to main content
SpringerLink
Log in

Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Multidrug resistance (MDR) is known as a problem limiting the success of therapy in patients treated long term with chemotherapeutic drugs. The drug resistance is mainly due to the overexpression of the 170 kDa P-glycoprotein (Pgp), which causes a reduction in drug accumulation in the cancer cells. In this study, novel chemical modulator(s) from bitter melon (Momordica charantia L.) extracts obtained from leaves, fruits and tendrils were tested for their abilities to modulate the function of Pgp and the MDR phenotype in the multidrug-resistant human cervical carcinoma KB-V1 cells (high Pgp expression) in comparison with wildtype drug-sensitive KB-3-1 cells (lacking Pgp).

Methods

The KB-V1 and KB-3-1 cells were exposed to bitter melon extracts in the presence of various concentrations of vinblastine, and cytotoxicity was assessed by means of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Relative resistance was calculated as the ratio of the IC50 value of the KB-V1 cells to the IC50 value of the KB-3-1 cells. Accumulation and efflux of vinblastine in KB-V1 and KB-3-1 cells were measured using a [3H]-vinblastine incorporation assay.

Results

The leaf extracts increased the intracellular accumulation of [3H]-vinblastine in KB-V1 cells in a dose-dependent manner, but extracts from the fruits and tendrils had no effect. By modulating Pgp-mediated vinblastine efflux, the leaf extracts decreased the [3H]-vinblastine efflux in KB-V1 cells in a dose-dependent manner, but not in KB-3-1 cells. Treatment of drug-resistant KB-V1 cells with bitter melon leaf extracts increased their sensitivity to vinblastine, but similar treatment of KB-3-1 cells showed no modulating effect. The fruit and tendril extracts did not affect the MDR phenotype in either cell line.

Conclusion

The leaf extracts from bitter melon were able to reverse the MDR phenotype, which is consistent with an increase in intracellular accumulation of the drug. The exact nature of the active components of bitter melon leaf extracts remains to be identified.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2a, b
Fig. 3a, b

Similar content being viewed by others

References

  1. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589–601

    CAS  PubMed  Google Scholar 

  2. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573–582

    Article  CAS  PubMed  Google Scholar 

  3. Bourhis J, Benard J, Hartmann O, Boccon-Gibod L, Lemerle J, Riou G (1989) Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 81:1401–1405

    CAS  PubMed  Google Scholar 

  4. Chan HS, Thorner PS, Haddad G, Ling V (1990) Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8:689–704

    CAS  PubMed  Google Scholar 

  5. Chu TM, Lin TH, Kawinski E (1994) Detection of soluble P-glycoprotein in culture media and extracellular fluids. Biochem Biophys Res Commun 203:506–512

    Article  CAS  PubMed  Google Scholar 

  6. Clynes M, Daly C, NicAmhlaoibh R, Cronin D, Elliott C, O’Connor R, O’Doherty T, Connolly L, Howlett A, Scanlon K (1998) Recent developments in drug resistance and apoptosis research. Crit Rev Oncol Hematol 28:181–205

    Article  CAS  PubMed  Google Scholar 

  7. Cole SP (1992) The 1991 Merck Frosst Award. Multidrug resistance in small cell lung cancer. Can J Physiol Pharmacol 70:313–329

    CAS  PubMed  Google Scholar 

  8. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650–1654

    CAS  PubMed  Google Scholar 

  9. Cunnick JE, Sakamoto K, Chapes SK, Fortner GW, Takemoto DJ (1990) Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia). Cell Immunol 126:278–289

    CAS  PubMed  Google Scholar 

  10. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199

    CAS  PubMed  Google Scholar 

  11. Jilka C, Strifler B, Fortner GW, Hays EF, Takemoto DJ (1983) In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res 43:5151–5155

    CAS  PubMed  Google Scholar 

  12. Larsen AK, Escargueil AE, Skladanowski A (2000) Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 85:217–229

    Article  CAS  PubMed  Google Scholar 

  13. Lee-Huang S, Huang PL, Chen HC, Huang PL, Bourinbaiar A, Huang HI, Kung HF (1995) Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 161:151–156

    Article  CAS  PubMed  Google Scholar 

  14. Lehnert M (1998) Chemotherapy resistance in breast cancer. Anticancer Res 18:2225–2226

    CAS  PubMed  Google Scholar 

  15. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113:2011–2021

    CAS  PubMed  Google Scholar 

  16. Loe DW, Deeley RG, Cole SP (1996) Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 32A:945–957

    Article  CAS  PubMed  Google Scholar 

  17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275

    CAS  PubMed  Google Scholar 

  18. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD (1990) Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A 87:7160–7164

    CAS  PubMed  Google Scholar 

  19. Plouzek CA, Ciolino HP, Clarke R, Yeh GC (1999) Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur J Cancer 35:1541–1545

    Article  CAS  PubMed  Google Scholar 

  20. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145–152

    CAS  PubMed  Google Scholar 

  21. Schoenlein PV (1994) Role of gene amplification in drug resistance. In: Goldstein LJ, Ozols RF (eds) Anticancer drug resistance: advances in molecular and clinical research. Kluwer, Boston, MA, pp 167–200

  22. Schoenlein PV, Shen DW, Barrett JT, Pastan I, Gottesman MM (1992) Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. Mol Biol Cell 3:507–520

    CAS  PubMed  Google Scholar 

  23. Shi H, Hiramatsu M, Komatsu M, Kayama T (1996) Antioxidant property of Fructus momordicae extract. Biochem Mol Biol Int 40:1111–1121

    CAS  PubMed  Google Scholar 

  24. Singh A, Singh SP, Bamezai R (1998) Momordica charantia (Bitter Gourd) peel, pulp, seed and whole fruit extract inhibits mouse skin papillomagenesis. Toxicol Lett 94:37–46

    Article  CAS  PubMed  Google Scholar 

  25. Varma MV, Ashokraj Y, Dey CS, Panchagnula R (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48:347–359

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the Thai Research Council. We also thank Dr. Michael M. Gottesman and Dr. Suresh V. Ambudkar (National Cancer Institute, NIH) for the gift of the KB-3-1 and KB-V1 cell lines, and some of the chemicals used in the study.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

    Pornngarm Limtrakul, Orawan Khantamat & Komsak Pintha

Authors
  1. Pornngarm Limtrakul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orawan Khantamat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Komsak Pintha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pornngarm Limtrakul.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Limtrakul, P., Khantamat, O. & Pintha, K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother Pharmacol 54, 525–530 (2004). https://doi.org/10.1007/s00280-004-0848-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0848-4

Keywords

Search

Navigation